Figure 4. METase enhanced the inhibitory effect of Pemetrexed on thymidylate synthase and cell apoptosis.

(A) Cell apoptosis in CD133+ SGC7901 cells treated with control, METase–/Pemetrexed–NPs and scFV–METase–/Pemetrexed–NPs. (B) ³H-thymidine assay was performed on CD133+ SGC7901 cells in untreated control (scFV–NPs), pemetrexed (scFV–pemetrexed–NPs), and combination therapy with METase (scFV–METase/pemetrexed–NPs). (C) The protein levels of thymidylate synthase (TS) and c-caspase 3 in gastric cancer cells. (D) Cell apoptosis in CD133+ MKN45 cells treated with control, METase–/Pemetrexed–NPs and scFV–METase–/Pemetrexed–NPs. (E) ³H-Thymidine assay was performed on CD133+ MKN45 cells in untreated control (scFV–NPs), pemetrexed (scFV–pemetrexed–NPs), and combination therapy with METase (scFV–METase/pemetrexed–NPs). (F) The protein levels of thymidylate synthase (TS) and c-caspase 3 in gastric cancer cells.All data were expressed as mean ± standard error (SE); *P<0.05, **P<0.01 comparison between groups. β-Actin was used for internal control in Western blot.